Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1633 1638 1687
This examiner grants 36% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17965377 | ENGINEERING STEM CELL T CELLS WITH MULTIPLE T CELL RECEPTORS | Final Rejection | The Regents of the University of California |
| 17800872 | IN-SERIES SYNTHETIC RECEPTOR AND-GATE CIRCUITS FOR EXPRESSION OF A THERAPEUTIC PAYLOAD BY ENGINEERED CELLS | Non-Final OA | The Regents of the University of California |
| 17775236 | METHODS AND COMPOSITIONS RELATING TO SELECTIVE INTRACELLULAR DELIVERY OF CD38 INHIBITORS | Final Rejection | Ohio State Innovation Foundation |
| 17786347 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | Non-Final OA | Novartis AG |
| 17261790 | COMPOSITIONS AND METHODS INVOLVING TRANSFORMING EXTRACELLULAR VESICLES | Final Rejection | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 18449940 | DEAD GUIDES FOR CRISPR TRANSCRIPTION FACTORS | Non-Final OA | Massachusetts Institute of Technology |
| 17687246 | COMPOSITION AND METHODS OF GENOME EDITING OF B-CELLS | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 18567470 | Tissue Extracts and Related Methods | Non-Final OA | ALLOSOURCE |
| 18008422 | USE OF RECOMBINANT HUMAN ACID SPHINGOMYELINASE TO IMPROVE SKELETAL MYOFIBER REPAIR | Final Rejection | CHILDREN'S NATIONAL MEDICAL CENTER |
| 17056749 | IMPROVED CELL THERAPY COMPOSITIONS FOR HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS | Non-Final OA | CHILDREN'S NATIONAL MEDICAL CENTER |
| 17905407 | CRISPR/CAS9 SYSTEM FOR MULTISTRAIN HIV-1 TREATMENT | Final Rejection | Board of Regents of the University of Nebraska |
| 18340417 | GENOME-EDITED INVARIANT NATURAL KILLER T (INKT) CELLS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | Non-Final OA | Washington University |
| 18448811 | COMPOSITIONS AND METHODS FOR ENHANCING GAMMA DELTA T CELLS IN THE GUT | Non-Final OA | KING'S COLLEGE LONDON |
| 17756138 | AKT INHIBITORS FOR ENHANCING CHIMERIC T CELL PERSISTENCE | Final Rejection | H. Lee Moffitt Cancer Center and Research Institute, Inc. |
| 17907121 | Targeted Destruction of Viral RNA by CRISPR-Cas13 | Non-Final OA | University of Rochester |
| 17776569 | COMPOSITIONS AND USES THEREOF FOR TREATING, PROGNOSING AND DIAGNOSING PULMONARY HYPERTENSION | Non-Final OA | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 17774848 | METHOD FOR PRODUCING CYTOTOXIC EFFECTOR MEMORY T-CELLS FOR CAR T-CELL TREATMENT OF CANCER | Final Rejection | BAYLOR COLLEGE OF MEDICINE |
| 17910459 | DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS COMPRISING IL-13 AND CHLOROTOXIN FOR CANCER TREATMENT | Non-Final OA | City of Hope |
| 17842225 | METHODS FOR TREATING EYE DISEASE | Non-Final OA | The United States Government as Represented by the Department of Veterans Affairs |
| 17612465 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DBA USING GATA1 GENE THERAPY | Final Rejection | THE CHILDREN'S MEDICAL CENTER CORPORATION |
| 17837093 | THERAPEUTIC CELL COMPOSITIONS AND METHODS OF MANUFACTURING AND USE THEREOF | Final Rejection | CREATE Medicines, Inc. |
| 17648247 | METHODS FOR MODULATING THE FUNCTION OF BIOLOGICAL REGULATORY NETWORKS IN HEALTH AND DISEASE BY EXPLOITING THEIR MEMORY PROPERTIES | Non-Final OA | Trustees of Tufts College |
| 18476065 | Method for Producing Stem Cell Clones Suitable for Induction of Differentiation into Somatic Cells | Non-Final OA | Megakaryon Corporation |
| 18537754 | SELECTION BY ESSENTIAL-GENE KNOCK-IN | Non-Final OA | Editas Medicine, Inc. |
| 18009320 | CHIMERIC ANTIGEN RECEPTOR CELL | Final Rejection | UCL Business Ltd |
| 16470933 | THERAPEUTIC CELLS | Final Rejection | UCL Business Ltd |
| 18501621 | ADMINISTRATION OF TUMOR INFILTRATING LYMPHOCYTES WITH MEMBRANE BOUND INTERLEUKIN 15 TO TREAT CANCER | Non-Final OA | OBSIDIAN THERAPEUTICS, INC. |
| 16631861 | METHODS AND COMPOSITIONS FOR TREATING ADDICTIONS | Final Rejection | BAR ILAN UNIVERSITY |
| 17997103 | REPEAT DOSING OF HYPOIMMUNOGENIC CELLS | Non-Final OA | Sana Biotechnology, Inc. |
| 17901424 | TREATMENT OF EXCESSIVE NEOVASCULARIZATION | Final Rejection | Mesoblast, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy